Loading...

HPS3/TIMI55-REVEAL

Randomized EValuation of the Effects of Anacetrapib through Lipid-modification

Welcome to the REVEAL Study website

Assessibility statement for the REVEAL website.

The REVEAL study is an international clinical trial that aims to find out if treating cholesterol with a new drug called anacetrapib will drive down the risk of heart attacks, deaths from heart disease and other vascular diseases.

The results of the REVEAL main trial were announced at the European Society of Cardiology congress in Barcelona on Tuesday 29th August 2017 and were simultaneously published in the New England Journal of Medicine. You may read or download a copy of the paper from http://www.nejm.org/doi/full/10.1056/NEJMoa1706444. The results are summarised in our press release, which is available in the Download section of this website.

A presentation on the ‘Impact of ADCY9 on Response to Anacetrapib Among 20,000 Participants in the HPS3/TIMI55-REVEAL Trial’ was delivered at the American College of Cardiology Scientific Session on 18 March 2019.

The results of the REVEAL post-trial follow-up were presented at the AHA Scientific Sessions in November 2019. The slides are available in the Download section of this website.

Data sharing requests will be considered after results from the post-trial follow-up phase have been published. See our Data Access Policy for more information.

What does the REVEAL study involve?

  • REVEAL involves over 30,000 men and women who already have some form of circulatory disease.

  • Participants were recruited from over 430 hospitals and clinics in the UK, North America, China, Germany, Italy and Scandinavia.

  • All study participants were given atorvastatin (a commonly used "statin" drug) to ensure good control of LDL ("bad") cholesterol.

  • Participants also received either anacetrapib or matching placebo (dummy) tablets daily (allocated randomly).

  • The primary aim of the study is to see whether fewer participants given anacetrapib have heart attacks, revascularization procedures or die from coronary heart disease than do those given the placebo tablets.

  • All participants stopped study treatment prior to February 2017 and direct participant follow-up was completed in April 2019. However, in the UK we will continue to collect information on health outcomes via registries and NHS sources. See the Download section for the REVEAL Data Privacy Notice for participants.

Downloads
 

The following downloads are available:

Frequently Asked Questions

What is the purpose of the study?

The study is called the REVEAL trial. It is investigating whether the drug anacetrapib (a CETP inhibitor) in combination with a statin can prevent vascular disease in high risk patients.

REVEAL is the largest study looking into the possible benefits of boosting good cholesterol and further lowering bad cholesterol to prevent heart attacks and strokes in people who have suffered these conditions before, and who are already taking statins. This means that REVEAL is uniquely positioned to answer questions about the contribution of good and bad cholesterol on the risk of serious cardiovascular diseases. 

^Back to FAQ

Who is running and who is funding the study?

The Clinical Trial Service Unit (CTSU) in the Nuffield Department of Population Health (NDPH) at the University of Oxford is coordinating this study and has overall responsibility for the administration and coordination of the study. There is a Steering Committee to oversee the trial conduct and an independent Data Monitoring Committee perform regular analyses on data collected so far to check that the study tablets aren't causing any illness.

Funding for this study is provided by Merck Sharp & Dohme Corp. to cover the administrative and coordination costs of the trial. The University of Oxford is acting as the sponsor of this study.

^Back to FAQ

Where is the REVEAL trial registered?

The REVEAL Trial is registered with the following bodies:

• ISRCTN (International Standard Randomised Controlled Trial Number): 48678192
• ClinicalTrials.gov: NCT01252953
• EU Clinical Trials Register: 2010-023467-18
• UKCRN (UK Clinical Research Network): 10598

^Back to FAQ

What if there is a problem?

If you have any concerns about any possible side-effects of treatment or any complaint about the way you have been dealt with during the study, please call the study team on Freefone 0800­ 585­ 323 (UK).

^Back to FAQ

The results of the REVEAL main trial were announced at the European Society of Cardiology congress in Barcelona at 07:30 British Summer Time on Tuesday 29th August 2017 and were simultaneously published in the New England Journal of Medicine. You can read or download a copy of the paper from http://www.nejm.org/doi/full/10.1056/NEJMoa1706444. The results are summarised in our press release, available in the Download section.

You can also view a table of adverse events and reactions by MedDRA classification.

Accessibility Statement for the REVEAL website (www.revealtrial.org)


NDPH’s commitment to accessibility
The Nuffield Department of Population Health (NDPH) is committed to making our websites and digital services as accessible as possible. Our aim is to combine excellent user experiences with high levels of accessibility and inclusivity, so everyone can use our digital services, whatever their abilities or disabilities.

Adapt your experience to your needs
Some people are likely to get the most accessible experience by customising their computer to suit their individual needs, for example, to get the site dictated to them, to change the colour-scheme, or increase the size of the text. If that sounds like it would be useful to you, we recommend you visit AbilityNet for advice on making your devices easier to use if you have a disability.

In addition, major operating systems produce the following guidance:

Advice for Microsoft users
Advice for Apple users
Advice for Linux users
Advice for Android users

Improving accessibility
We are aware that some of the content on this website may not be fully accessible and believe that the site is partially compliant with accessibility standards. Much of the content was created before September 2018. This includes PDF documents which aren’t essential to the service we provide. Occasional updates to this site are being made, but the majority of the content is not being updated regularly. The content of this site will be integrated with the Nuffield Department of Population Health website which is being maintained on an ongoing basis. This change will be made by September 2021.

Feedback and contact information

If you experience any difficulties accessing any of the information on this website, or need the information in a different format, please email the NDPH Communications Team. We will consider your request and get back to you within 14 days.

Enforcement procedure

The Equality and Human Rights Commission (EHRC) is responsible for enforcing the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018 (the ‘accessibility regulations’). If you have a complaint and are not happy with how we respond to it, please contact the Equality Advisory and Support Service (EASS).

Preparation of this accessibility statement

This statement was last reviewed on 30 September 2020.

24-hour Freefone service: 0800­ 585 323

By post: REVEAL, Clinical Trial Service Unit (CTSU), Richard Doll Building, University of Oxford, Roosevelt Drive, OXFORD, OX3 7LF

By email: reveal@ndph.ox.ac.uk

Clinical Trial Service Unit (CTSU) website: https://www.ctsu.ox.ac.uk

Medical Research Council Population Health Research Unit (MRC PHRU) website: https://www.mrc-phru.ox.ac.uk